{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:40:07Z","timestamp":1750538407209,"version":"3.41.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Few articles in literature describe the potential usefulness of <jats:sup>18<\/jats:sup>F-choline PET\/CT and particularly <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET\/CT in imaging of clear cell renal cell carcinoma (ccRCC). We report a unique comparison in literature between the 2 radiotracers in a patient who underwent left nephrectomy with diagnosis of ccRCC, grade 3. <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET\/CT confirmed its emerging role in imaging ccRCC, as the incidentally detected renal neoplasm showed a significant higher uptake in comparison to <jats:sup>18<\/jats:sup>F-choline PET\/CT, inducing surgical indication.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004515","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T20:13:49Z","timestamp":1675368829000},"page":"e178-e180","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["18F-Choline Versus 68Ga-PSMA-11 PET\/CT Imaging Comparison in Incidental Clear Cell Renal Cell Carcinoma"],"prefix":"10.1097","volume":"48","author":[{"given":"Luca","family":"Urso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Christian","family":"Rocca","sequence":"additional","affiliation":[{"name":"Urology Unit, Surgical Department, University Hospital of Ferrara, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Licia","family":"Uccelli","sequence":"additional","affiliation":[{"name":"Translational Medicine Department, Ferrara University, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Ippolito","sequence":"additional","affiliation":[{"name":"Urology Unit, Surgical Department, University Hospital of Ferrara, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirco","family":"Bartolomei","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Oncological Medical and Specialists Department, University Hospital of Ferrara, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13550-017-0329-5","article-title":"Correlation of 99mTc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression","volume":"7","year":"2017","journal-title":"EJNMMI Res"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00432-022-03958-7","article-title":"Role of PSMA-ligands imaging in renal cell carcinoma management: current status and future perspectives","volume":"148","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.euf.2018.08.004","article-title":"The role of radiolabeled prostate-specific membrane antigen positron emission tomography\/computed tomography for the evaluation of renal cancer","volume":"6","year":"2020","journal-title":"Eur Urol Focus"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12149-015-1017-z","article-title":"Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET\/CT","volume":"29","year":"2015","journal-title":"Ann Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s00259-020-05165-3","article-title":"18F-PSMA-1007 PET\/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3390\/diagnostics11071142","article-title":"PSMA-PET\/CT in patients with recurrent clear cell renal cell carcinoma: histopathological correlations of imaging findings","volume":"11","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/RLU.0000000000004162","article-title":"Incremental value of 18F-PSMA-1007 PET\/CT in detection of metastatic renal cell carcinoma to the brain","volume":"47","year":"2022","journal-title":"Clin Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/RLU.0000000000003002","article-title":"18F-PSMA 1007 in suspected renal cell carcinoma","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"E65","DOI":"10.1097\/RLU.0000000000003354","article-title":"18F-PSMA-1007 PET\/CT for initial staging of renal cell carcinoma in an end-stage renal disease patient","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1097\/RLU.0000000000004055","article-title":"Pituitary metastasis of renal cell carcinoma characterized by 18F-prostate-specific membrane antigen-1007 PET\/CT","volume":"47","year":"2022","journal-title":"Clin Nucl Med"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/RLU.0000000000003664","article-title":"Utility of 18F-prostate-specific membrane antigen 1007 in imaging of tumor thrombus of renal cell carcinoma","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/CCO.0000000000000518","article-title":"PET imaging in renal cancer","volume":"31","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"bib13-20250621","first-page":"339","article-title":"The usefulness of 11C-choline PET\/CT for detecting metastasis and treatment monitoring of renal cell carcinoma: report of two cases","volume":"64","year":"2018","journal-title":"Hinyokika Kiyo"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12149-010-0375-9","article-title":"Initial experience with 18F-fluoroethylcholine PET\/CT in staging and monitoring therapy response of advanced renal cell carcinoma","volume":"24","year":"2010","journal-title":"Ann Nucl Med"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12149-018-1287-3","article-title":"Diagnostic performance of 11C-choline PET\/CT and FDG PET\/CT for staging and restaging of renal cell cancer","volume":"32","year":"2018","journal-title":"Ann Nucl Med"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.juro.2017.08.079","article-title":"Comprehensive evaluation of prostate specific membrane antigen expression in the vasculature of renal tumors: implications for imaging studies and prognostic role","volume":"199","year":"2018","journal-title":"J Urol"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00259-020-04916-6","article-title":"Comprehensive evaluation of 68Ga-PSMA-11 PET\/CT parameters for discriminating pathological characteristics in primary clear-cell renal cell carcinoma","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/RLU.0000000000003814","article-title":"68Ga-PSMA uptake patterns of clear cell renal carcinoma across different histopathological subtypes","volume":"47","year":"2022","journal-title":"Clin Nucl Med"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40336-020-00372-2","article-title":"Impact of PSMA PET\/CT in prostate cancer patient\u2019s clinical management: a pictorial essay of interesting cases with histologic confirmation","volume":"8","year":"2020","journal-title":"Clin Transl Imaging"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1097\/RLU.0000000000003053","article-title":"68Ga-PSMA PET\/CT and 18F-FDG PET\/CT in renal cell carcinoma","volume":"45","year":"2020","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:05:31Z","timestamp":1750536331000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004515","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}